ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Silver Sponsor

Bronze Sponsor

Pharmaceutical News

  • Shared digital NHS prescribing record could avoid nearly 1 million annual drug errors
    on March 27, 2024 at 9:00 am

    Implementing a single shared digital prescribing record across the NHS in England could avoid nearly 1 million drug errors every year, stopping up to 16,000 fewer patients from being harmed, and saving up to 22 lives every year, suggests a modelling study, published online in BMJ Quality & Safety. The figures, which are based on the assumption that such a system could reduce medication errors by at least 10%, and by as much as 50%, could also save £millions for the NHS, say the researchers.

  • Global study could change how children with multiple sclerosis are treated
    on March 26, 2024 at 9:00 am

    A ground-breaking study - the largest of its kind globally - has found children with multiple sclerosis (MS) have better outcomes if treated early and with the same high-efficacy therapies as adults. There are a limited number of therapies approved for children with MS, with only one considered to be of high-efficacy - meaning highly effective.

  • FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
    on March 25, 2024 at 9:00 am

    The U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle.

  • Reducing the side effects of breast and ovarian cancer treatment
    on March 22, 2024 at 9:00 am

    Some anti-cancer treatments not only target tumour cells but also healthy cells. If their effects on the latter are too strong, their use can become limiting. A team from the University of Geneva (UNIGE), in collaboration with Basel-based FoRx Therapeutics, has identified the mechanism of action of PARP inhibitors, used in particular for breast and ovarian cancer in patients carrying the BRCA gene mutation.

  • Experimental gene therapy for giant axonal neuropathy shows promise in NIH clinical trial
    on March 21, 2024 at 9:00 am

    An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit in a clinical trial led by the National Institutes of Health (NIH). Currently, there is no treatment for GAN and the disease is usually fatal by 30 years of age. Fourteen children with GAN, ages 6 to 14 years, were treated with gene transfer therapy at the NIH Clinical Center and then followed for about six years to assess safety.